GSK’s (GSK) “Hold” Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft restated their hold rating on shares of GSK (LON:GSK) in a report released on Wednesday,Digital Look reports. Deutsche Bank Aktiengesellschaft currently has a GBX 2,000 price target on the stock.

GSK has been the subject of several other reports. Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,500 price objective on shares of GSK in a research report on Wednesday, July 29th. Citigroup cut their price target on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, GSK currently has an average rating of “Hold” and a consensus target price of GBX 2,048.57.

GSK Stock Performance

Shares of GSK stock opened at GBX 1,846.50 on Wednesday. The business’s 50 day simple moving average is GBX 1,920.49 and its 200 day simple moving average is GBX 1,983.22. GSK has a one year low of GBX 1,445 and a one year high of GBX 2,282. The stock has a market capitalization of £73.96 billion, a PE ratio of 15.67, a PEG ratio of 1.24 and a beta of 0.29. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73.

GSK (LON:GSK) last released its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 earnings per share (EPS) for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. As a group, research analysts forecast that GSK will post 175.980975 earnings per share for the current year.

Insider Transactions at GSK

In related news, insider Jeannie Lee acquired 802 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were bought at an average price of GBX 5,069 per share, with a total value of £40,653.38. Also, insider Vishal Sikka bought 1,266 shares of GSK stock in a transaction dated Monday, June 22nd. The stock was purchased at an average price of GBX 5,069 per share, with a total value of £64,173.54. Insiders have purchased 3,618 shares of company stock valued at $13,481,942 in the last 90 days. 0.20% of the stock is currently owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.